

**SB 463 STAFF MEASURE SUMMARY**

**Senate Committee On Health Care**

---

**Prepared By:** Daniel Dietz, LPRO Analyst

**Meeting Dates:** 3/1, 3/8

---

**WHAT THE MEASURE DOES:**

Prohibits health benefit plans from imposing prior authorization or other utilization review requirements on coverage of proton beam therapy that do not apply to coverage of radiation therapy.

*REVENUE: No revenue impact*

*FISCAL: No fiscal impact*

**ISSUES DISCUSSED:**

- Availability, cost, and utilization review for proton beam therapy and photon therapy

**EFFECT OF AMENDMENT:**

No amendment.

**BACKGROUND:**

In 2021, the Legislative Assembly passed Senate Bill 2, which provides that coverage of proton beam therapy may be subject to prior authorization or other utilization review only if "the prior authorization or utilization review applied to proton beam therapy is no more restrictive than the prior authorization or utilization review applied to radiation therapy."

Senate Bill 463 requires health benefit plans that cover radiation therapy for prostate cancer to cover proton beam therapy "on a basis no less favorable than the coverage of radiation therapy including with respect to prior authorization or other utilization review requirements."